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Summary
Background Treatment guidelines recommend a stepwise approach to primary biliary cholangitis: all patients begin 
treatment with ursodeoxycholic acid (UDCA) monotherapy and those with an inadequate biochemical response after 
12 months are subsequently considered for second-line therapies. However, as a result, patients at the highest risk 
can wait the longest for effective treatment. We determined whether UDCA response can be accurately predicted 
using pretreatment clinical parameters.
Methods We did logistic regression analysis of pretreatment variables in a discovery cohort of patients in the UK with 
primary biliary cholangitis to derive the best-fitting model of UDCA response, defined as alkaline phosphatase less 
than 1·67 times the upper limit of normal (ULN), measured after 12 months of treatment with UDCA. We validated 
the model in an external cohort of patients with primary biliary cholangitis and treated with UDCA in Italy. 
Additionally, we assessed correlations between model predictions and key histological features, such as biliary injury 
and fibrosis, on liver biopsy samples.
Findings 2703 participants diagnosed with primary biliary cholangitis between Jan 1, 1998, and May 31, 2015, were 
included in the UK-PBC cohort for derivation of the model. The following pretreatment parameters were associated with 
lower probability of UDCA response: higher alkaline phosphatase concentration (p<0·0001), higher total bilirubin 
concentration (p=0·0003), lower aminotransferase concentration (p=0·0012), younger age (p<0·0001), longer interval 
from diagnosis to the start of UDCA treatment (treatment time lag, p<0·0001), and worsening of alkaline phosphatase 
concentration from diagnosis (p<0·0001). Based on these variables, we derived a predictive score of UDCA response. 
In the external validation cohort, 460 patients diagnosed with primary biliary cholangitis were treated with UDCA, with 
follow-up data until May 31, 2016. In this validation cohort, the area under the receiver operating characteristic curve for 
the score was 0·83 (95% CI 0·79–0·87). In 20 liver biopsy samples from patients with primary biliary cholangitis, the 
UDCA response score was associated with ductular reaction (r=–0·556, p=0·0130) and intermediate hepatocytes 
(probability of response was 0·90 if intermediate hepatocytes were absent vs 0·51 if present).
Interpretation We have derived and externally validated a model based on pretreatment variables that accurately 
predicts UDCA response. Association with histological features provides face validity. This model provides a basis to 
explore alternative approaches to treatment stratification in patients with primary biliary cholangitis.
Funding UK Medical Research Council and University of Milan-Bicocca.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Introduction
Primary biliary cholangitis is an autoimmune 
liver disease characterised by destructive cholangitis 
affecting the small intrahepatic bile ducts, leading to 
chronic cholestasis and progressive fibrosis.1 Many 
patients eventually develop end-stage liver disease 
with attendant need for liver transplantation.2 First-line 
treatment for primary biliary cholangitis is with 
ursodeoxycholic acid (UDCA), a hydrophilic bile acid 
that improves liver biochemistry, delays histological 
progression, and improves liver-transplantation-free 
survival.3–6 The biochemical response to treatment 
with UDCA (the UDCA response) strongly predicts 
long-term outcome. Thus, liver-transplantation-free 
survival is similar between patients with normal or 
near-normal liver biochemistry on UDCA and the 
general population, but is significantly reduced in those 
with abnormal liver biochemistry on treatment.7
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The increased risk of progressive liver disease in 
patients with inadequate UDCA response has prompted 
the development of second-line therapies. Obeticholic 
acid is already used in clinical practice, and others will 
follow. The most recent guidelines therefore recommend 
that patients with inadequate UDCA response be 
considered for second-line therapies; the conventional 
period to demonstrate inadequate UDCA response is 
12 months.8 However, with this approach, patients at the 
highest risk of disease progression (ie, those with active 
disease that does not respond to UDCA) wait the longest 
for effective treatment.
At present, there are no clinical means to identify, 
before treatment, patients who are unlikely to respond to 
UDCA and who therefore might benefit from early 
introduction of second-line therapy. We aimed to 
determine whether inadequate UDCA response can be 
predicted using pretreatment clinical parameters; to 
understand the nature of those parameters; and to 
develop a predictive model that would enable accurate 
identification of patients unlikely to respond to UDCA, in 
whom alternative approaches to treatment stratification 
might be explored. Finally, we sought to test the biological 
plausibility of the model by looking for correlations 
between model predictions and key histological features, 
such as biliary injury and fibrosis, on liver biopsy samples 
from patients with primary biliary cholangitis.
Methods
Study design and participants
For derivation, we used data from the UK-PBC Research 
Cohort, part of the UK-PBC project.9 In the discovery 
cohort, we included only those participants who were 
diagnosed with primary biliary cholangitis between 
Jan 1, 1998, and May 31, 2015, with follow-up data until 
May 31, 2016. We restricted the analysis to this period to 
ensure that all patients in the derivation cohort had equal 
access to UDCA following diagnosis, as UDCA was been 
registered in 1997.10 For external validation, we used data 
from a well characterised cohort of patients recruited by 
the Italian PBC Study Group (appendix p 6).11 In the 
validation cohort, to replicate real-world conditions, we 
included patients treated with UDCA diagnosed before or 
after 1998, with follow-up data until May 31, 2016.
We defined primary biliary cholangitis and definite 
primary biliary cholangitis–autoimmune hepatitis 
overlap syndrome according to EASL guidelines.8 We 
defined probable primary biliary cholangitis–autoimmune 
hepatitis overlap syndrome as the combination of 
pretreatment immunoglobulin G more than twice the 
upper limit of normal (ULN) and aminotransferases 
more than five time the ULN. The date of diagnosis of 
primary biliary cholangitis was the date of detection of 
antimitochondrial antibodies or the date of the diagnostic 
liver biopsy, whichever occurred first.
The UK-PBC project and Italian PBC Study were done 
in accordance with the Declaration of Helsinki and the 
principles of good clinical practice. In both studies, all 
participants provided written informed consent. The 
UK-PBC project was approved by the Oxford C research 
ethics committee (07/H0606/96) and by each collaborating 
hospital. The Italian PBC Study was approved by the 
research ethics committee of the University of Milan 
Bicocca (ICH/232/11) and by each collaborating hospital.
Procedures 
Baseline (T0) data were those immediately before starting 
UDCA therapy. Clinical data and laboratory data were 
collected at diagnosis (alkaline phosphatase, amino-
transferases, bilirubin, albumin, platelet count, creatinine, 
Research in context
Evidence before this study
We searched PubMed for the term primary biliary cholangitis 
from 1998 to 2017. Treatment guidelines recommend that 
patients with primary biliary cholangitis who have an 
inadequate response to ursodeoxycholic acid (UDCA) after 
12 months consider second-line therapy. However, with this 
approach many patients at highest risk of disease progression 
(ie, those with active disease that does not respond to UDCA) 
wait the longest for effective treatment. At present, there are 
no reliable means to identify patients before treatment who are 
unlikely to respond to UDCA, and so might benefit from early 
introduction of second-line therapy.
Added value of this study
We have derived a model based on pretreatment clinical 
variables that accurately predicts response to UDCA, with an 
area under the receiver operating characteristic curve of 
0·83 (0·79–0·87) in external validation. We observed 
correlation between model predictions and key pathological 
features, such as the extent of fibrosis, ductular reaction, and 
cytokeratin 7 intermediate hepatocytes, providing face 
validity. The model uses readily available parameters, such as 
alkaline phosphatase, bilirubin, aminotransferases, patient’s 
age at diagnosis, and the interval from diagnosis to the start of 
treatment. That delayed initiation of UDCA reduced the 
probability of response shows the importance of early, 
effective therapy.
Implications of all the available evidence
Future response to UDCA treatment can be predicted in 
patients with primary biliary cholangitis. This provides a basis to 
explore alternative approaches to treatment stratification, such 
as earlier introduction of second-line therapy. The model might 
even be useful in precision medicine initiatives to identify 
predictive biomarkers for treatment or risk stratification in 
primary biliary cholangitis.
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sodium, splenomegaly, and ascites), immediately before 
starting UDCA therapy (alkaline phosphatase, amino-
transferases, bilirubin), and after 12 months of treatment 
with UDCA (alkaline phosphatase, aminotransferases, 
bilirubin). The endpoint was UDCA response, defined as 
alkaline phosphatase less than 1·67 times the ULN,12 
measured after 12 months of treatment with UDCA 
(ALPT12). Because of controversy about the best ALPT12 
cutoff to define UDCA response, we modelled three other 
cutoffs (ALPT12 ≤1 × ULN; ALPT12 <1·5 × ULN; and ALPT12 
<2 × ULN; appendix pp 13–15).
To account for interlaboratory variability, the alkaline 
phosphatase, alanine aminotransferase, aspartate amino-
transferase, and total bilirubin were expressed as a 
multiple of their respective ULNs. We used a composite 
variable, aminotransferases, which was the alanine amino-
transferase concentration when available; other wise, the 
aspartate aminotransferase concentration was used.
To assess correlations with histological features, we 
evaluated formalin-fixed and paraffin-embedded liver 
biopsy samples from patients with primary biliary 
cholangitis at the Department of Clinical Medicine, 
Sapienza University of Rome (Rome, Italy). Biopsies were 
done at the time of diagnosis in treatment-naive patients 
with serological or biochemical suspicion of primary 
biliary cholangitis. Biopsy samples were collected 
consecutively from Jan 1, 1996, until Dec 31, 2006, when 
the unit policy changed and liver biopsies were no 
longer routinely done for patients with primary biliary 
cholangitis. Biopsies with fewer than nine complete portal 
tracts were excluded. Automated quantitative assessment 
of fibrosis was done in Sirius Red stained sections with 
an image analysis algorithm.13 We evaluated ductular 
reaction and intermediate hepatocytes (previously known 
as biliary metaplasia) by cytokeratin 7 immunoreactivity 
(appendix p 9).14–16 Histological evaluation was done 
independently by two authors blinded to the clinical data. 
In the case of disagreement, consensus was obtained by 
joint review of sections. Consensus on the grade and stage 
of the biopsy sample was reached in all cases.
Statistical analysis
We described continuous variables by median and IQR 
because most were not normally distributed. Categorical 
variables were described by absolute numbers and 
percentages. To compare groups, we used the χ² test for 
categorical variables (or Fisher’s exact test in the case of 
sparse tables) and Student’s t test for continuous variables 
(or Wilcoxon rank-sum test when a significant departure 
from normality was detected). We used Spearman’s 
correlation to measure the strength and direction of 
monotonic association between two ranked variables.
We did multivariate analysis using logistic regression. 
We selected variables on the basis of non-automated 
backward selection, taking correlation structure 
among covariates and clinical interpretation of their 
effects into account. We explored possible interactions 
following a clinically driven approach. Different 
parametric transformations were considered to 
model the effect of continuous covariates, including 
first-degree and second-degree fractional polynomials. 
We did influence analysis, and underweighted overly 
influential obser vations according to Huber weights to 
limit the risk of local overfitting. We identified poorly 
predicted observations by the standardised deviance 
Derivation cohort 
(n=2703)
Validation cohort 
(n=460)
Age (years) 56·80 (49·52–64·16) 52·0 years (44·00–60·00)
Female 2409/2703 (89·1%) 423/460 (92·0%)
Treatment 
time lag* (days)
75 (0–258) ··
ALPdiag (× ULN) 1·85 (1·21–3·25) 1·78 (1·18–3·06)
ATdiag (× ULN) 1·40 (0·90–2·25) 1·38 (0·85–2·27)
TBdiag (× ULN) 0·53 (0·37–0·76) 0·60 (0·44–0·82)
PLTdiag (× 10³ per µL) 272 (225–324) 237 (199–286)
ALBdiag (g/L) 41 (38–44) 41 (38–43)
Creatinine (µmol/L) 76 (67–86) ··
Sodium (mEq/L) 139 (138–141) ··
Splenomegaly 263/2287 (11·5%) ··
Ascites 48/2285 (2·1%) ··
ALPT0 (× ULN) 1·91 (1·25–3·32) ··
ATT0 (× ULN) 1·42 (0·92–2·25) ··
TBT0 (× ULN) 0·53 (0·37–0·76) ··
ALPT12 (× ULN) 1·22 (0·88–1·88) 1·12 (0·77–1·76)
ATT12 (× ULN) 0·78 (0·54–1·23) 0·76 (0·52–1·08)
TBT12 (× ULN) 0·48 (0·35–0·65) 0·57 (0·41–0·73)
Data are median (IQR) or n (%). ALBdiag=albumin at diagnosis. ALPdiag=alkaline 
phosphatase at diagnosis. ALPT12=alkaline phosphatase after 12 months of 
treatment with ursodeoxycholic acid (UDCA). PLTdiag=platelet count at diagnosis. 
ATdiag=aminotransferases at diagnosis. ATT12=aminotransferases after 12 months of 
treatment with UDCA. TBdiag=total bilirubin at diagnosis. TBT12=total bilirubin after 
12 months of treatment with UDCA. ULN=upper limit of normal. 
Table 1: Characteristics of the derivation and validation cohorts
Parameter 
estimate
SE Wald 
statistic
p value
Intercept 0·774 0·425 ·· ··
ln(ALPdiag [× ULN]) –2·730 0·138 –19·765 <0·0001
1/√TBdiag [× ULN]) 0·600 0·165 3·637 0·0003
ln(ATdiag [× ULN]) 0·350 0·108 3·236 0·0012
Age (years) 0·028 0·006 5·074 <0·0001
Treatment time 
lag (years)
–0·154 0·035 –4·362 <0·0001
ΔALP (× ULN) –0·557 0·073 –7·588 <0·0001
The results are from the logistic model based on baseline characteristics. 
Derivation cohort n=2703, used observations n=2640, missing 2·3%. ALPdiag=alkaline 
phosphatase concentration at diagnosis. TBdiag=total bilirubin concentration at 
diagnosis. ATdiag=aminotransferase concentration at diagnosis. ΔALP=change in 
alkaline phosphatase concentration from diagnosis to start of treatment.
Table 2: Estimated parameters for UDCA response in the model 
derivation cohort 
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residuals. In both internal and external validation, we 
evaluated model calibration and predictive ability using 
calibration belts17 and area under the receiver operating 
characteristic curve (AUROC). We used non-parametric 
stratified bootstrapping to compute confidence bands 
for AUROC. The appendix (pp 7–8) contains further 
details of the statistical analyses.
We did all analyses using SAS (version 9.4) and R 
(version 3.4).
Role of the funding source
The funders had no role in study design, data collection, 
analysis, or interpretation, preparation of the report, or 
the decision to publish. The corresponding author had 
full access to the raw data and had final responsibility 
for the decision to submit for publication.
Results
For the UK-PBC derivation cohort, we identified 
3073 UDCA-treated participants diagnosed with primary 
biliary cholangitis between Jan 1, 1998, and 31 May, 2015. 
We excluded 330 participants because ALPT12 was not 
available, 25 participants because treatment with UDCA 
lasted less than 9 months, and 15 participants because 
they started UDCA after liver transplantation. No 
participants had definite or probable primary biliary 
cholangitis–autoimmune hepatitis overlap syndrome. The 
derivation cohort therefore consisted of 2703 participants.
Median age at diagnosis was 56·80 years 
(IQR 49·52–64·16) and 2409 (89·7%) of participants were 
female (table 1). The median time from diagnosis to the 
start of treatment (the treatment time lag) was 75 days 
(IQR 0–258). As expected, the treatment time lag was longer 
in participants with primary biliary cholangitis diagnosed at 
the start of the study period than later (appendix p 10). The 
proportion of patients whose alkaline phosphatase increased 
between diagnosis and the start of treatment—and the size 
of this change—was greater in those with a longer treatment 
time lag (appendix p 10). Overall, 1902 (70·4%) of 
2703 participants achieved the endpoint, ALPT12 less than 
1·67 × ULN, measured at a median of 13·4 months 
(IQR 11·8–16·9) after the start of treatment.
We did logistic regression analysis of explanatory 
variables to derive the best-fitting model to predict UDCA 
response. The following variables were excluded because 
more than 5% of data were missing: splenomegaly 
(429 [16%] of 2703 had missing data), ascites (422 [16%]), 
immunoglobulins (791 [29%]), and international 
normalised ratio (635 [23%]). The remaining variables 
were used in multivariable analysis. Of these, platelet 
count at diagnosis had the most missing data (130 [5%]).
The best-fitting logistic regression model included 
five variables: alkaline phosphatase at diagnosis (ALPdiag; 
p<0·0001), total bilirubin at diagnosis (TBdiag; p=0·0003), 
aminotransferases at diagnosis (ATdiag; p=0·0012), age at 
diagnosis (p<0·0001), treatment time lag (p<0·0001), and 
change in alkaline phosphatase concentration from the 
time of diagnosis to the start of treatment (ΔALP, p<0·0001; 
table 2). Log transformation was preferred for ALPdiag and 
ATdiag; the inverse of the squared root for TBdiag. A linear 
effect was confirmed for the treatment time lag and ΔALP. 
Overall, 63 observations were excluded from final fitting 
because of incomplete data in one or more of the selected 
variables. Influence analysis identified 29 observations as 
highly influential in the parameter estimates of the final 
model. Thus, to avoid potential model instability owing to 
local overfitting, observations were weighted according to 
Huber weights: in 2349 of 2641 of observations, Huber 
weights were equal to 1; in the remaining 292, weights had 
a median value of 0·71 (IQR 0·54–0·85)
Figure 1: Relationship between the variables selected in the best-fitting logistic regression model and the 
probability of UDCA response
In each plot the remaining variables were set to their mean values.
0 5 10 15 20
Alkaline phosphatase at diagnosis (× ULN)
0
0·25
0·50
0·75
A
1·00
Pr
ed
ict
ed
 re
sp
on
se
 p
ro
ba
bi
lit
y
–5·0 –2·5 0 2·5 5·0
Δ alkaline phosphatase (× ULN)
B
0 2 4 6 8
Total bilirubin at diagnosis (× ULN)
0
0·25
0·50
0·75
C
1·00
Pr
ed
ict
ed
 re
sp
on
se
 p
ro
ba
bi
lit
y
0 2 4 6 8
Aminotransferases at diagnosis (× ULN)
D
30 40 6050 70 80
Age at diagnosis (years)
0
0·25
0·50
0·75
E
1·00
Pr
ed
ict
ed
 re
sp
on
se
 p
ro
ba
bi
lit
y
0 1 32 4 5
Treatment time lag (years)
F
Articles
www.thelancet.com/gastrohep   Published online July 12, 2018   http://dx.doi.org/10.1016/S2468-1253(18)30163-8 5
Higher ALPdiag, ΔALP, and TBdiag were associated with 
lower likelihood of UDCA response (figure 1A–C). 
Unexpectedly, higher ATdiag was associated with higher 
likelihood of UDCA response (figure 1D). Older age at 
diagnosis was associated with UDCA response, as was 
a shorter treatment time lag (figure 1E, 1F). The 
Hosmer-Lemeshow test showed no evidence of lack of fit 
to the data (p=0·4967). Inspection of residuals identified 
138 (5·2%) of 2703 poorly predicted observations, 
consistent with the expected percentage of 5%. For 
36 of these outliers, participants responded to UDCA 
despite predicted probability of less than 0·21, whereas 
102 did not respond to UDCA despite a predicted 
probability of more than 0·80. None of the study 
characteristics distinguished these outliers from the 
remainder of the study cohort. We did not identify 
statistically significant interactions in the final model. 
However, we found that the main effect of the selected 
variables was less pronounced when the estimated 
probability of response was high (table 3, appendix p 12); 
this effect depends on the features of the logistic model.
We used the regression coefficients of the selected 
variables (table 2) to develop a predictive score of 
UDCA response for each patient according to the 
following formula:
Based on the UDCA Response Score (URS), the predicted 
probability of response can be estimated as:
Internal validation of the URS demonstrated high 
discrimination ability with an AUROC of 0·87 (95% CI 
0·86–0·89; figure 2A). Calibration of the model in the 
derivation cohort showed that event rates were correctly 
estimated by the predicted probabilities except at very 
extreme values, for which there was a slight tendency to 
underestimate the proportion (figure 2B). Table 3 shows 
how each variable affects the probability of UDCA 
response in different clinical scenarios. A calculator 
based on the URS is available online.
In clinical practice, information at the time of 
diagnosis might be missing. We therefore tested the 
URS by substituting measurements from the treatment 
start date (T0) for those from the date of diagnosis 
(eg, TBT0 in place of TBdiag), fixing the treatment time lag 
to 0. Using T0 measurements, the URS still had high 
discrimination ability, with an AUROC of 0·87 (95% CI 
0·86–0·89). Additionally, we developed an alternative 
model, URST0, fitted in the derivation cohort using only 
data from the treatment start date (appendix p 17). The 
URST0 contained the same variables as the URS, with 
similar parameter estimates. The URS may therefore be 
used with measurements from the treatment start date, 
setting and the treatment time lag to 0.
UDCA response score = 0·77 + 0·60 × (√TBdiag)–1 
– 2·73 × ln(ALPdiag) + 0·35 × ln(ATdiag) + 0·03 ×  
age – 0·15 × (treatment time lag) – 0·56 × ∆ALP
Probability (response) =
Exp(URS)
1 + Exp(URS)
ATdiag TBdiag Recipient 
age (years)
ALPdiag ΔALP Treatment 
time lag
Estimated 
probability of UDCA 
response (95% CI)
Relative 
probability 
change
Varying aminotransferases
High probability of response
Low aminotransferases 0·5 0·5 60 2 0 0 0·76 (0·71–0·81) ref
High aminotransferases 3 0·5 60 2 0 0 0·86 (0·83–0·89) 13%
Low probability of response
Low aminotransferases 0·5 2 40 3 1 1 0·16 (0·09–0·23) ref
High aminotransferases 3 2 40 3 1 1 0·27 (0·20–0·33) 40%
Varying time lag
High probability of response
Short time lag and low ΔALP 2 0·5 60 2 0 0·1 0·84 (0·81–0·86) ref
Long time lag and high ΔALP 2 0·5 60 2 1 2 0·68 (0·64–0·73) –19%
Low probability of response
Short time lag and low ΔALP 1 2 40 3 0 0·1 0·33 (0·25–0·41) ref
Long time lag and high ΔALP 1 2 40 3 1 2 0·17 (0·12–0·23) –48%
The main effect of each variable in the model is less pronounced when the estimated probability of response is high. For example, if the ATdiag is increased from 0·5 × ULN to 
3 × ULN, the relative change in the probability of response is 13% when the estimated probability of response is high (76% and 86%, respectively), whereas the relative change 
in the probability of response is 40% when the estimated probability of response is low (16% and 27%, respectively). Similarly, if the treatment time lag is increased from 
0·1 (1 month) to 2 years, the relative change in the probability of response is –19% when the estimated probability of response is high (84% and 68%, respectively), whereas 
the relative change in the probability of response is –48% when the estimated probability of response is low (33% and 17%, respectively). ALPdiag=alkaline phosphatase 
concentration at diagnosis. ATdiag=aminotransferase concentration at diagnosis. TBdiag=total bilirubin concentration at diagnosis. ULN=upper limit of normal. ΔALP=change in 
ALP concentration from diagnosis to the start of treatment. Treatment time lag=time from diagnosis to the start of treatment.
Table 3: Clinical scenarios showing the effect of aminotransferase concentration and time lag on the estimated probability of UDCA response
For the UDCA Response Score 
calculator see http://www.mat.
uniroma2.it/~alenardi/URS.html
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We validated the URS in an external population of 
984 patients treated with UDCA from the Italian PBC 
Study Group, diagnosed before or after 1998, with 
follow-up data until May 31, 2016. Variables available for 
these patients included demographic characteristics, 
liver biochemistry at diagnosis, and the liver bio-
chemistry during treatment. Data on the dose of UDCA 
and liver biochemistry at the start of treatment were not 
available. Application of the proposed score requires the 
ALPT0 to calculate the change; therefore, we included in 
the validation cohort only those patients who had 
started UDCA within 1 year of diagnosis (n=460) and 
fixed the ΔALP to zero. No participants had definite 
or probable primary biliary cholangitis–autoimmune 
hepatitis overlap syndrome.
Median age at diagnosis in the validation cohort was 
52·0 years (IQR 44·00–60·00), and 423 (92·0%) of 
460 were female. 335 (73%) of 460 participants 
responded to treatment. The validation cohort was 
younger than the derivation cohort with slightly lower 
PLTdiag, ALPT12, and ATT12, and slightly higher TBdiag and 
TBT12 (table 1, appendix p 19). The AUROC for the URS 
in the Italian cohort was 0·83 (95% CI 0·79–0·87), 
confirming a high ability to discriminate (figure 2C). 
The calibration plot showed no significant departure 
between the observed response rate and the predicted 
probability of response, confirming that the URS is well 
calibrated (figure 2D).
To confirm that the Italian cohort was suitable for 
validation even without ∆ALP measurements, we tested 
the URS in a subgroup of 615 patients from the 
validation cohort with treatment time lag greater than 0 
but less than 10 years, still setting the ∆ALP and the 
treatment time lag to zero (effectively excluding these 
two variables). The model performed reasonably well 
in this subgroup, with an AUROC of 0·81 (95% CI 
0·77–0·84), although less well than the proposed model 
with all variables. This finding shows that the URS has 
high predictive performance, even without information 
on ∆ALP and treatment time lag. ALPdiag, TBdiag, and 
ATdiag are the variables with strongest effects in the URS, 
whereas the effect of the treatment time lag is limited 
(figure 1F). Based on these observations, we believe that 
the external validation was done appropriately.
When we fitted models using three other cutoffs for 
ALPT12, all models included the same variables, with the 
size and direction of effect of each variable similar 
across all models (appendix pp 13–15).
To evaluate potential bias resulting from use of the 
aspartate aminotransferase as a surrogate for the alanine 
aminotransferase in the composite aminotransferase 
variable, we refitted the model in a subgroup of 
2319 participants from the derivation cohort for whom 
ALTdiag values were available. We found that parameter 
estimates in the refitted model were similar to those in the 
original model: the parameter estimate for ln(ALTdiag) was 
0·359 (SE 0·114, p=0·0017; appendix p 18), similar to the 
parameter estimate for ln(ATdiag) in the whole derivation 
cohort, which was 0·350 (SE 0·108, p=0·0012; table 2).
Using liver biopsy samples from 20 patients to assess 
the relationship with histological features, we found no 
correlation between the URS and the Ishak grade or 
Ludwig stage of disease (appendix p 20). There was, 
however, significant correlation of the URS with extent of 
ductular reaction (figure 3A), and extent of fibrosis 
(appendix p 20). The URS was also associated with the 
presence of intermediate hepatocytes, with median 
probability of response of 0·90 in patients with absent or 
minimal intermediate hepatocytes, compared with a 
median probability of response of 0·51 in those with 
clustered or diffuse intermediate hepatocytes (figure 3B). 
Moreover, there was correlation between the extent of 
ductular reaction and the ALPdiag, ALPT12, Ludwig stage, 
interface hepatitis, portal inflammation, and the extent of 
fibrosis (appendix p 20).
Discussion
We have shown that, in patients with primary biliary 
cholangitis, the state of disease at baseline has a significant 
impact on the likelihood of response to UDCA, and that 
parameters associated with inadequate UDCA response 
Figure 2: Performance of the model
(A) AUROC for the prediction of response to ursodeoxycholic acid (UDCA) calculated by UDCA Response Score in 
the derivation cohort, using stratified bootstrapping to estimate the confidence interval. (B) The predicted versus 
observed probability of response in the derivation cohort. “Never” means that the calibration belt never goes 
above or under the bisector; this suggests no evidence of miscalibration. (C) AUROC curve for the prediction of 
treatment response calculated by UDCA Response Score in the external validation cohort. (D) The predicted versus 
observed probability of response in the external validation cohort. AUROC=area under the receiver operating 
characteristic curve.
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can be integrated into an accurate predictive model, which 
we validated in an external cohort. Estimates from the 
model correlated with tissue-based markers of disease 
severity, providing face validity. Delay in starting UDCA 
therapy was associated with a higher risk of inadequate 
UDCA response, suggesting that delay to optimal 
treatment might reduce the likelihood of response.
The strongest predictor of UDCA response was 
the baseline alkaline phosphatase concentration; the 
probability of response declined sharply as the alkaline 
phosphatase increased. This strong inverse relationship 
suggests that—at least in patients with untreated primary 
biliary cholangitis—the alkaline phosphatase concen-
tration accurately reflects the severity of biliary injury, 
apparently a key determinant of whether choleretic 
therapy will be effective. Consistent with this, UDCA 
response was less likely if the alkaline phosphatase 
concentration increased between diagnosis and the start 
of treatment (possibly reflecting progression of biliary 
injury) and if treatment was delayed (possibly because 
this allows the biliary injury to progress). The latter 
observation has implications for the timing of second-line 
therapy—ie, if a patient is unlikely to respond to UDCA 
they could be switched to second-line therapy sooner, 
with the hope of improving their prognosis.
Having excluded patients with definite or probable 
autoimmune hepatitis overlap from the analysis, the 
finding that higher concentrations of aminotransferases 
were associated with higher likelihood of UDCA 
response was unexpected. One possibility is that high 
aminotransferase concentrations are associated with a 
hepatitic phenotype of primary biliary cholangitis that is 
more responsive to choleretic treatment. Alternatively, 
aminotransferase concentrations might be high at an 
early, hepatitic stage of the disease process, when 
choleretic treatment might be more effective. Either way, 
the finding is important because it emphasises that, in 
treatment-naive patients with primary biliary cholangitis, 
high aminotransferase concentrations do not invariably 
signify autoimmune hepatitis overlap, and additional 
evidence is needed to justify immunosuppression. It is 
perhaps no surprise that high bilirubin was associated 
with low likelihood of UDCA response: in patients with 
primary biliary cholangitis, high bilirubin might reflect 
advanced ductopenia or end-stage liver disease, and it is 
plausible that choleresis is less effective in either setting.
Figure 3: Associations between UCDA Response Score and histological features of disease
(A) Correlation of estimated probabilities of response to UDCA based on the UDCA Response Score with the extent of ductular reaction expressed as volume fraction 
of liver parenchyma. The panel on the right shows immunohistochemical staining for CK7 in liver biopsy samples. A different extension of CK7-positive ductular 
reaction is present (arrows). (B) Association of estimated probability of UDCA response with the presence of intermediate hepatocytes. The middle panels show 
representative images of immunohistochemical staining for CK7 in biopsy samples with or without intermediate hepatocytes (arrows). In the panel on the right, 
intermediate hepatocytes are confirmed in double immunofluorescence stains by the coexpression of albumin (arrowheads). Arrows indicate ductular reaction in the 
portal tract and at the interface with liver parenchyma. CK7=cytokeratin 7. DR=ductular reaction. IH=intermediate hepatocytes. UDCA=ursodeoxycholic acid. 
PT=portal tract.
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We have previously shown that younger age at 
diagnosis predicts inadequate UDCA response.9 We 
confirmed this finding in this study. The relationship 
between age at diagnosis and likelihood of UDCA 
response might be caused by the effect of hormones, 
such that high oestrogen levels increase resistance to 
treatment, an effect that is lost when patients present 
after menopause.18 Immune senescence may also be 
important; T-cell exhaustion has a central role in 
determining outcome in autoimmune disease.19
We explored interactions that we considered biologically 
plausible but did not detect statistically significant effects. 
However, we showed that the effect of each variable in the 
final model depends on the estimated probability of 
response. For example, changes in ATdiag or the treatment 
time lag have relatively small effects when the estimated 
probability of UDCA response is high, but relatively large 
effects when the estimated probability of UDCA response 
is low. The same is true for the ALPdiag, TBdiag, ΔALP, and 
age of the patient (data not shown). This finding shows 
that, in patients already at risk, no variable can be taken for 
granted, particularly the treatment time lag, which is the 
only variable that the clinician can influence. These 
apparently differential effects are explained by the logistic 
link between the effect of covariates and the probability of 
response, and the different weights of the selected variables 
in the fitted model. They are biologically plausible; for 
example, in patients with high aminotransferases, jaundice 
may be attributable to hepatitic activity, which is amenable 
to treatment. Conversely, if the aminotransferases are 
not high, jaundice might indicate ductopenia or end-stage 
liver disease, which is less amenable to treatment. 
Taking the combination of different factors into account 
is what makes multivariable models so valuable for 
precision medicine.
We identified a correlation between the URS and the 
extent of ductular reaction. Ductular reaction represents a 
trans-amplifying population of cells, consisting of strings 
of cells with irregular lumens and a highly variable 
phenotypic profile.20 The origin of ductular reaction is 
debated, but it is a hallmark of severe biliary injury. In our 
study, ductular reaction was also strongly correlated with 
ALPdiag and the observed as well as predicted UDCA 
treatment response. These observations emphasise the 
value of alkaline phosphatase concentration as a 
biomarker for biliary injury in patients with primary 
biliary cholangitis and suggest that the severity of biliary 
injury is a major determinant of responsiveness to 
choleretic treatment. However, only 20 biopsy samples 
were available for analysis, which is a limitation of the 
study. More pretreatment biopsy samples need to be 
assessed before conclusions can be drawn. Histological 
grading and staging in this study should ideally have been 
undertaken using the Nakanuma system,21 which includes 
cholangitis and chronic cholestasis. However, this was 
not possible because the orcein stain was not routinely 
done in our pathology centre at the time the biopsy 
samples were collected and the remaining tissue was 
insufficient to obtain additional sections for research. 
Rather than using different grading and staging systems, 
we opted to use the well established Ishak system to grade 
the samples (evaluating interface hepatitis, focal necrosis, 
lobular inflammation, and portal inflammation) and the 
Ludwig system to stage them.1 We recommend that future 
studies use systems that score necroinflammatory activity 
and chronic cholestasis.
In this work, we mainly used a cutoff of ALPT12 less than 
1·67 × ULN to define response, because this is how UDCA 
response has been defined in clinical trials of second-line 
agents and, as the recent industry standard, it will probably 
be used to decide which patients should receive second-
line drugs. However, this cutoff is debated: Lammers and 
colleagues12 showed that an ALPT12 less than 2·0 × ULN best 
discriminates positive and negative outcomes in primary 
biliary cholangitis, whereas the European Association for 
the Study of the Liver suggests that an ALPT12 more than 
1·5 × ULN is the threshold at which long-term risk of 
death or liver transplantation becomes higher than that in 
a sex-matched and age-matched healthy population.8 
Given the strong correlation between alkaline phosphatase 
concentration and histological features of biliary injury, it 
might be argued that the threshold should be less than or 
equal to 1 × ULN (ie, biochemical remission). When we 
repeated our analysis using these alternative cutoffs the 
respective models included the same variables and were 
similar in performance.
Since 2016, regulatory authorities have approved 
obeticholic acid for use in patients with primary biliary 
cholangitis with inadequate response to, or intolerance of, 
UDCA. More recently, Corpechot and colleagues22 
presented data from the BEZURSO trial, a phase 3 trial of 
bezafibrate versus placebo in combination with UDCA, in 
which normalisation of alkaline phophatase occurred in 
67 (67%) of 100 patients on bezafibrate versus none on 
placebo. Several novel agents for primary biliary cholangitis 
are in phase 2 or 3 trials, such as Seladelpar 
(a PPARδ agonist),23 Elafibranor (a PPARαδ agonist), and 
LJN452 (a non-bile acid FXR agonist). The current 
approach to management of primary biliary cholangitis is 
to start treatment with an optimal dose of UDCA in all 
patients, risk-stratify after 12 months of treatment using 
any of several binary or continuous scoring systems, then 
offer second-line therapy to high-risk patients (ie, those with 
abnormal liver biochemistry despite UDCA). Given the 
current and forthcoming availability of more efficacious 
disease-modifying treatments, now may be an appropriate 
time to review this approach. A predictive model enabling 
baseline identification of patients likely to need enhanced 
therapy could inform a novel treatment strategy (eg, early 
addition of second-line treatment). In this study, we 
present such a model. We recognise that ∆ALP and 
treatment time lag would be redundant in clinical practice, 
but we retain them in the model to emphasise the 
importance of delaying effective treatment.
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In conclusion, we have developed an accurate model 
to identify patients unlikely to respond to UDCA 
monotherapy at baseline. This model (or an iteration of it) 
could inform future treatment stratification in patients 
with primary biliary cholangitis.
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